Mexico's Diario Oficial of March 20, lists notices from the Secretary of the Economy as follows:
The Alcohol and Tobacco Tax and Trade Bureau will hold a webinar March 26 from 2-3 p.m. ET on allowable changes that can be made to labels without applying for a new COLA. TTB has expanded the list of allowable changes to reduce regulatory burden and help products reach market faster, it said. The webinar will detail each of the 26 allowable changes to labels (here). To register, email Nicole.Burckhardt@ttb.gov. Space is limited, but TTB will hold additional sessions in April, it said.
The Federal Trade Commission agreed to settlements with three apparel and footwear vendors for violations of the Fur Act. According to the FTC, Neiman Marcus, DrJays.com and Eminent said its products used “faux fur,” when they instead used real fur. None of the three companies disclosed the animal from which the fur was derived, and Neiman Marcus didn’t disclose the fur’s country of origin. Per the terms of the proposed settlements, none of the companies admitted their guilt. If the settlements are finalized, each company will be prohibited for 20 years from violating the Fur Act and the Fur Rules.
The International Trade Administration published notices in the March 20 Federal Register on the following AD/CV proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms, or effective dates will be detailed in another ITT article):
Antidumping duty cash deposit rates from the final results of the International Trade Administration’s administrative review and new shipper reviews of frozen fish fillets from Vietnam (A-552-801) will be effective March 21, according to a notice set for publication in that day’s Federal Register. In the final results, the ITA found AD rates of $0.19/kg for Vinh Hoan, $1.34/kg for Anvifish, and $0.77/kg for twelve separate rates but not individually-reviewed companies. The Vietnam-wide rate remained $2.11/kg. The new shipper reviews found AD rates of $1.37/kg for An Phu, $3.87/kg for Docifish, and $1.81/kg for An Phat.
Consumer Product Safety Commission announced the following voluntary recalls March 19 (country of manufacture in parentheses):
On March 19 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration posted presentations from its March 11-12 meeting in Chicago on its Jan. 16 proposed rules on produce safety and preventative controls in human food (see 13010805 and 13010429, respectively. The presentations include overviews, regulatory impact analyses, and FDA educational and technical assistance efforts for each rule. The meeting was the second in a series of three held throughout the country on the proposals. The first was held in Washington, D.C., Feb. 28-March 1, and the next meeting will be held in Portland March 27-28 (see 13020627).
The Food and Drug Administration found violations of Current Good Manufacturing Practice regulations at two of Canadian pharmaceutical manufacturer Apotex’s facilities, and may withhold approval of new drug applications and refuse admission as a result, said FDA in a warning letter. “The evidence suggests that Apotex has failed to implement adequate global and sustainable corrective and preventive actions, and that it continues to manufacture and distribute pharmaceutical product without upholding its legal obligation to comply with CGMP,” FDA said.
A Chinese beauty product manufacturer’s devices will be subject to refusal at the border for failure to register their product with FDA and violations of Medical Device Reporting regulations, said the Food and Drug Administration in a warning letter. According to FDA, Nanhai Meishida Beauty Equipment did not indicate that it had trained employees in MDR procedures. It also markets a “13 in 1 Beauty Instrument” with a “high-frequency function” that induces “sterilization and evaporation,” as well as “hyperemization,” among other things. The company didn’t get permission from FDA in the form of premarket approval or an investigational device exemption, FDA said.